Facebook
Twitter
LinkedIn
ForwardASH 2021 Highlights
THIS IS A VIRTUAL ACTIVITY
Description
The care of patients with hematologic malignancies is evolving rapidly. This continuing medical education activity will discuss new developments in the diagnosis and treatment of hematologic malignancies, as presented at the 2021 Annual Meeting of the American Society of Hematology (ASH).
During this one-day virtual course, faculty will share the latest updates in lymphoma, leukemia, myeloma, and stem cell transplantation. Through case-based presentations and Q&A, attendees will gain a deeper understanding of emerging treatments available for blood cancers and blood disorders and learn how these new therapies can be integrated into daily practice
Target Audience
This activity is directed toward hematologists, medical oncologists, internists, nurse practitioners, oncology nurses, and other interested healthcare providers.
Learning Objectives
At the conclusion of this course, attendees will be able to:
- Describe an overview and highlight of the recent medical advances presented at the 2021 Annual Meeting of the American Society of Hematology (ASH), which will help physicians achieve better patient outcomes.
- Recognize appropriate management and treatment options for hematologic malignancies and utilize these approaches in routine clinical practice.
- Review new therapies and approaches in non-malignant hematology.
About the Center for Hematologic Oncology at Dana-Farber Brigham Cancer Center
We offer advanced, specialized care for patients with all types of hematologic malignancies, including leukemia and similar bone marrow disorders, lymphoma, multiple myeloma, Waldenström’s macroglobulinemia, and other related blood disorders.
Dana-Farber Brigham Cancer Center is at the forefront of stem cell transplantation, performing more than 500 transplants each year. Our team of specialists are national leaders in basic and clinical research designed to bring cutting-edge, innovative therapies to patients with blood cancers. The program is committed to working closely with referring oncologists to jointly devise clinical strategies to improve the care of our patients.
Additional Information
Dana-Farber Brigham Cancer Center and Mass General Brigham
| 7:00am | Registration |
| 7:30 | Welcome and Introduction |
| 7:40 | Transplant Highlights Mahasweta Gooptu, MD |
| 8:15 | Acute Lymphocytic Leukemia and Myeloproliferative Neoplasms Daniel J. DeAngelo, MD, PhD |
| 9:05 | Chronic Lymphocytic Leukemia Inhye Ahn, MD |
| 9:40 | BREAK |
| 9:55 | Myelodysplastic Syndrome and Acute Myelogenous Leukemia Richard M. Stone, MD |
| 10:45 | Thrombosis and Hemostasis Maureen M. Achebe, MD, MPH |
| 11:20 | Multiple Myeloma Omar Nadeem, MD |
| 11:50 | Lymphoma Jennifer Crombie, MD |
| 12:25pm | Closing Remarks |
| 12:30pm | Adjourn |
Ann S. LaCasce, MD, MMSc - Course Director
Director, Dana-Farber/Mass General Brigham Hematology-Medical Oncology Fellowship Program,
Medical Oncologist, Adult Lymphoma Program,
Dana-Farber Brigham Cancer Center;
Associate Professor of Medicine, Harvard Medical School
Maureen Okam Achebe, MD, MPH
Clinical Director, Division of Hematology
Brigham and Women’s Hospital;
Assistant Professor of Medicine, Harvard Medical School
Inhye Ahn, MD
Medical Oncologist, Center for Chronic Lymphocytic Leukemia,
Dana-Farber Brigham Cancer Center;
Member of the Faculty of Medicine, Harvard Medical School
Jennifer Crombie, MD
Medical Oncologist, Lymphoma Program,
Dana-Farber Brigham Cancer Center;
Instructor in Medicine, Harvard Medical School
Daniel J. DeAngelo, MD, PhD
Chief, Division of Leukemia,
Dana-Farber Brigham Cancer Center;
Professor of Medicine, Harvard Medical School
Mahasweta Gooptu, MD
Medical Oncologist, Stem Cell Transplantation Program,
Dana-Farber Brigham Cancer Center;
Assistant Professor of Medicine, Harvard Medical School
Omar Nadeem, MD
Clinical Director, Myeloma Cellular Therapies Program, Multiple Myeloma Program,
Dana-Farber Brigham Cancer Center;
Instructor in Medicine, Harvard Medical School
Richard M. Stone, MD
Chief of Staff, Dana-Farber Cancer Institute;
Director, Translational Research, Adult Leukemia Program,
Dana-Farber Brigham Cancer Center;
Professor of Medicine, Harvard Medical School
In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Mass General Brigham designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 4.50 AMA PRA Category 1 Credit™
- 4.50 Participation